SRG-514 is under clinical development by SURGE Therapeutics and currently in Phase I for Ductal Carcinoma In Situ. According to GlobalData, Phase I drugs for Ductal Carcinoma In Situ have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SRG-514’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SRG-514 overview
SRG-514 is under development for the prevention of recurrence after breast conserving cancer surgery in breast carcinoma or ductal carcinoma in situ. The drug candidate is administered intraoperatively in the form of gel.
SURGE Therapeutics overview
SURGE Therapeutics (SURGE) is a provider of intraoperative immunotherapy services for cancer patients that offers an injectable biodegradable hydrogel and allows prolonged, localized free-up of most cancers immunotherapy. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of SRG-514’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.